The Green Park Collaborative and the National Hemophilia Foundation launch project to develop a PROM to measure mental health outlook.
This study was based on a systematic literature review of peer-reviewed articles relevant to VWD and pregnancy, published between January 1982 and May 2019.
Nationally recognized researcher Dr. Leonard Valentino to lead the Foundation into the future.
Groups argue patients need a quick resolution to ensure access to care.
The group of patients who participated in this study were teenagers living with hemophilia A and B, who averaged 16 years of age.
The activity is intended for emergency medicine physicians, hematologists, pediatricians, nurses, and other healthcare professionals who manage patients with hemophilia.
On December 23rd, the BioMarin submitted a Biologics License Application for valoctocogene roxaparvovec to the U.S. Food and Drug Administration.
Sangamo transferred the investigational new drug application for their hemophilia A gene therapy candidate to Pfizer, which will now lead its phase 3 clinical development.
NHF's Excellence Fellowships support projects in the areas of nursing, social work, and physical therapy.
Learn the latest data and advances in the development of gene therapy approaches for the treatment of hemophilia, and increase your ability to critically evaluate key considerations for incorporating gene therapy strategies into patient care
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car